- Previous Close
7.85 - Open
7.82 - Bid 7.66 x 100
- Ask 7.73 x 100
- Day's Range
7.44 - 7.89 - 52 Week Range
7.00 - 16.63 - Volume
1,057,096 - Avg. Volume
786,407 - Market Cap (intraday)
904.206M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-2.96 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.12
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
www.89bio.comRecent News: ETNB
View MorePerformance Overview: ETNB
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ETNB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ETNB
View MoreValuation Measures
Market Cap
904.21M
Enterprise Value
518.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.36%
Return on Equity (ttm)
-73.31%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-288.96M
Diluted EPS (ttm)
-2.96
Balance Sheet and Cash Flow
Total Cash (mrq)
423.77M
Total Debt/Equity (mrq)
9.94%
Levered Free Cash Flow (ttm)
-180.68M